I have another question here. The joint oncology drug review has now been contracted out to the Ontario government's cancer agency to make these decisions for everybody, I understand. Is that not the common drug review admitting it can't do cancer drugs? My question is, is the same thing true for biologics? Do the people who present those therapies feel that the common drug review is not as capable as they would like? Is the same thing true for drugs for rare diseases?
Dr. Billen would like to comment.